// App-Quantinova.ai

5597 : Biomarker results and preclinical rationale for combination lenvatinib and pembrolizumab in advanced endometrial carcinoma.

Researchers

Presenter

  • Vicky Makker

Principal Investigators

  • Allen Lee Cohn

  • Matthew H. Taylor

  • Yukinori Minoshima

  • Yu Kato

  • Ryo Dairiki

  • Michio Kanekiyo

  • Ayako Yachie

  • Kotaro Kodama

  • Pallavi Sachdev

  • Junji Matsui

  • Yasuhiro Funahashi

  • Drew W. Rasco

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Rocky Mountain Cancer Center, US Oncology, Denver, CO

  • Oregon Health and Science University, Portland, OR

  • Eisai Co. Ltd., Tsukuba, Ibaraki, Japan

  • Eisai Co. Ltd. Bunkyo, Tokyo, Japan

  • The Systems Biology Institute, Tokyo, Japan

  • Eisai Inc, Woodcliff Lake, NJ

  • START-South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX

Locations

  • United States

  • Japan

Companies

  • Eisai Co., Ltd.

  • Eisai Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Cancer antigen 15-3

  • Stromal interaction molecule 1

Drug/Treatment

  • Pembrolizumab

  • Lenvatinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT02501096

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved